Skip to main content

Table 3 Results of other recent chemoradiation trials, unresectable stage III (without cetuximab)

From: A review of clinical trials of cetuximab combined with radiotherapy for non-small cell lung cancer

Author, patient number Treatment Median survival (PFS)
Bepler et al. [41], 39 2 cycles induction carboplatin and gemcitabine, RT up to 74 Gy (mean 70) with weekly carboplatin and paclitaxel 22.7 mo
(14.3 mo)
Socinski et al. [42], 43 2 cycles induction carboplatin and paclitaxel, RT 74 Gy with weekly carboplatin and paclitaxel 24.3 mo
Krzakowski et al. [43], 54 2 cycles induction cisplatin and vinorelbine, RT 66 Gy with 2 cycles cisplatin and vinorelbine 23.4 mo
(12.5 mo)
Sejpal et al. [44], 62 Weekly carboplatin and paclitaxel, RT median 74 Gy with protons 24.4 mo
Segawa et al. [45], 99 RT 60 Gy with 4 cycles of concomitant cisplatin and docetaxel 26.8 mo
(13.4 mo)
Cho et al. [46], 49 Weekly carboplatin and paclitaxel, RT 60 Gy in 25 fractions 28.1 mo
(13.7 mo)
Gandara et al. [47], 83 RT 61 Gy with 2 cycles of concomitant cisplatin and etoposide, consolidation docetaxel 26 mo
(16 mo)
  1. RT: radiotherapy; PFS: progression-free survival